和血明目片联合康柏西普治疗湿性年龄相关性黄斑变性的疗效评价  

Efficacy Evaluation on the Treatment of Wet Age-related Macular Degeneration with Conbercept Combined with Hexue Mingmu tablets

作　　者：李盈龙 王光鑫 胡威 邵晨 彭小宁 刘帅 LI Yinglong;WANG Guangxin;HU Wei(Department of Ophthamology,The Third Affiliated,Hospital of Anhui Medical University,Hefei,Anhui 230001)

机构地区：[1]安徽医科大学第三附属医院眼科,安徽合肥230001

出　　处：《实用防盲技术》2024年第3期105-109,共5页Journal of Practical Preventing Blind

基　　金：合肥市科委基金应用医学项目(Hwk2021yb004);安徽医科大学校级科研基金(2020xkj067)。

摘　　要：目的评估观察和血明目片联合抗血管内皮生长因子药物康柏西普对湿性年龄相关性黄斑变性(wAMD)的治疗效果。方法选择收治的112例(112只眼)湿性AMD患者,按照随机数字表法分为实验组和对照组,每组56例(56只眼)。两组患者每月均给予玻璃体腔内注射康柏西普0.05ml,连续治疗3个月,实验组同时给予和血明目片口服治疗,3次/天,5粒/次,连续3个月。应当交接用药频次及剂量治疗结束后随访3个月观察最佳矫正视力(BCVA)、眼压(IOP)、黄斑区视网膜中央厚度(CRT)、黄斑出血面积、并发症、复发率等情况,并进行统计学评价。结果BCVA:两组在治疗后1周、1月、2月及3月较前均明显改善,在治疗后1月、2月、3月,实验组均优于对照组(t=2.501,t=2.621,t=4.464,P均<0.05)。CRT:两组在治疗后1周、1月、2月、3月均低于术前,在治疗后1月、2月、3月,实验组CRT低于对照组(t=1.899,t=2.018,t=2.590,P均<0.05)。眼底出血:治疗后3个月,黄斑出血面积比治疗前明显缩小,且实验组更明显(t=-3.497,P=0.001)。并发症及复发率:两组均出现一过性高眼压和结膜下出血,实验组的复发率要低于对照组。结论口服和血明目片可提高康柏西普治疗湿性AMD的疗效。Objective To evaluate the therapeutic efficacy of combining Hexue Mingmu Tablets with anti-vascular endothelial growth factor drug(Conbercept)in the treatment of wet age-related macular degeneration(wAMD).Methods A total of 112 patients(112 eyes)with wet AMD were selected and randomly divided into an experimental group and a control group using a random number table method,with 56 patients(56 eyes)in each group.Both groups received intravitreal injections of 0.05ml of Conbercept monthly for 3 consecutive months.Additionally,the experimental group was administered Hexue Mingmu Tablets orally,5 tablets per dose,three times daily,for 3 months.Patients were followed up for an additional 3 months after treatment completion to observe changes in best-corrected visual acuity(BCVA),intraocular pressure(IOP),central retinal thickness(CRT)in the macular area,macular bleeding area,complications,and recurrence rates.Statistical evaluation was performed.Results BCVA:Both groups showed significant improvement in BCVA at 1 week,1 month,2 months,and 3 months post-treatment compared to baseline.Notably,the experimental group demonstrated superior BCVA outcomes compared to the control group at 1 month,2 months,and 3 months posttreatment(t=2.501,t=2.621,t=4.464,P均<0.05).CRT:CRT values in both groups were significantly lower at 1 week,1 month,2 months,and 3 months post-treatment compared to baseline.Furthermore,the experimental group had lower CRT values than the control group at 1 month,2 months,and 3 months post-treatment(t=1.899,t=2.018,t=2.590,P均<0.05).Macular Bleeding:The macular bleeding area was significantly reduced at 3 months post-treatment compared to baseline in both groups,with a more pronounced reduction observed in the experimental group(t=-3.497,P=0.001).Complications and Recurrence Rate:Transient ocular hypertension and subconjunctival hemorrhage occurred in both groups,but the recurrence rate was lower in the experimental group.Conclusion The addition of oral Hexue Mingmu Tablets enhances the therapeutic effica

关 键 词：湿性年龄相关性黄斑变性 和血明目片 康柏西普 联合治疗 

分 类 号：R774.5[医药卫生—眼科]